top of page
The antibody-based cancer immunotherapies targeting the Programmed Cell Death1-Programmed Cell Death Ligand 1 (PD1-PDL1) interaction have shown unprecedented clinical success against several types of cancer. We aim to discover small-molecule inhibitors of PD1-PDL1 interaction that may offer several advantages as compared to antibodies, such as higher oral bioavailability, lower cost, better tumor infiltration, and relatively shorter half-life that is especially helpful in controlling any potential adverse immune reactions.
Dedicated Patil Lab members that carried out this cutting-edge research in cancer immunotherapy & beyond!
bottom of page